Bryan, Garnier & Co upgraded shares of AstraZeneca plc (LON:AZN) to a buy rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They currently have GBX 5,380 ($69.48) target price on the biopharmaceutical company’s stock, up from their previous target price of GBX 4,700 ($60.70).
Other equities analysts have also issued reports about the stock. Berenberg Bank upped their target price on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the stock a buy rating in a research report on Wednesday, May 17th. Liberum Capital reiterated a buy rating and set a GBX 5,500 ($71.03) target price on shares of AstraZeneca plc in a research report on Tuesday, May 23rd. UBS AG set a GBX 5,150 ($66.51) target price on shares of AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a research report on Thursday, July 13th. Finally, Credit Suisse Group reduced their target price on shares of AstraZeneca plc from GBX 5,000 ($64.57) to GBX 4,700 ($60.70) and set a neutral rating on the stock in a research report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. AstraZeneca plc has a consensus rating of Hold and an average price target of GBX 5,022.91 ($64.87).
AstraZeneca plc (AZN) opened at 4806.00 on Monday. The firm has a 50-day moving average of GBX 4,566.78 and a 200 day moving average of GBX 4,881.73. The firm’s market cap is GBX 60.84 billion. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.
The business also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.
In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.